Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Corebridge Financial Inc.

Corebridge Financial Inc. lifted its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 16.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,294 shares of the company’s stock after purchasing an additional 3,801 shares during the quarter. Corebridge Financial Inc.’s holdings in Zevra Therapeutics were worth $219,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZVRA. Charles Schwab Investment Management Inc. increased its holdings in Zevra Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company’s stock worth $842,000 after buying an additional 11,038 shares during the period. State Street Corp boosted its holdings in shares of Zevra Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after acquiring an additional 52,966 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter worth $94,000. Barclays PLC raised its holdings in shares of Zevra Therapeutics by 292.6% during the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after purchasing an additional 42,926 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after purchasing an additional 129,600 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on ZVRA shares. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group raised their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $22.29.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 61,273 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at $231,759.96. The trade was a 26.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 over the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $6.90 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The business’s 50 day moving average is $7.67 and its two-hundred day moving average is $8.14. The company has a market capitalization of $373.40 million, a P/E ratio of -3.50 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. Analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.